Autologous stem cell transplantation in NK/T‐cell lymphoma: Prognostic impact of EBV‐DNA in a multinational cohort—A study by the EBMT Lymphoma Working Party
Open Access
- 15 August 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (8) , e70184
Abstract
Natural killer (NK)/T‐cell lymphomas (NKTCLs) are rare, aggressive lymphomas prevalent in East Asia and South America. Despite improvements, largely due to asparaginase‐based therapies, outcomes for advanced disease remain poor, and the role of autologous stem cell transplantation (auto‐HCT) remains controversial. This study evaluated real‐world outcomes of auto‐HCT in NKTCL patients across Asia and Europe. We included 130 adult NKTCL patients undergoing auto‐HCT between 2011 and 2022 using data from the European Society for Blood and Marrow Transplantation (EBMT) registry and South Korean registry data. Median age was 51.3 years; 66.9% were male. Most patients (95.1%) had an Eastern Cooperative Oncology Group (ECOG) score 0–1; 65.3% had Stage III–IV disease. One prior therapy line was reported in 53.1%, and ≥2 lines in 46.9%. Asparaginase‐based regimens were used in 79.5% pretransplant. Responses at auto‐HCT included complete (59.7%), partial (27.9%) remission, and stable/progressive disease (12.4%). Epstein–Barr virus (EBV)‐DNA in the peripheral blood was reported in 37.3%. With a median follow‐up of 4.6 years, 3‐year overall survival (OS) and progression‐free survival (PFS) were 63.8% and 47.6%. Relapse and NRM rates at 3 years were 46.7% and 5.7%. Patients in complete remission had improved 3‐year OS (75.2%) compared to PR (52.8%) and stable/progressive disease (32.0%) (P = 0.007). Detectable EBV‐DNA in the blood at auto‐HCT was associated with poor outcomes (3‐year OS: 26.7% vs. 78.1% in patients with undetectable EBV‐DNA; P < 0.0001). Patients achieving complete remission and undetectable EBV‐DNA in the blood before auto‐HCT had a favorable survival, suggesting auto‐HCT may be a treatment option in selected high‐risk patients. This is the largest multinational cohort evaluating prognostic factors for auto‐HCT for NKTCL.Keywords
This publication has 32 references indexed in Scilit:
- Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study GroupBlood, 2012
- Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal TypeClinical Cancer Research, 2012
- Autologous and Allogeneic Stem-Cell Transplantation for Transformed Chronic Lymphocytic Leukemia (Richter's Syndrome): A Retrospective Analysis From the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow TransplantationJournal of Clinical Oncology, 2012
- Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal typeBlood, 2011
- Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group StudyJournal of Clinical Oncology, 2011
- Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009The Lancet Oncology, 2009
- Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled StudyTransplantation and Cellular Therapy, 2008
- Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasmsBone Marrow Transplantation, 2006
- Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its valueAnnals of Oncology, 2003